Skip Navigation


Rheumatology Advance Access originally published online on March 3, 2008
Rheumatology 2008 47(4):451-453; doi:10.1093/rheumatology/ken073
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/4/451    most recent
ken073v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baslund, B.
Right arrow Articles by Nielsen, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baslund, B.
Right arrow Articles by Nielsen, C. H.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells

B. Baslund1, J. Gregers2 and C. H. Nielsen3

1Department of Rheumatology, Rigshospitalet and the University of Copenhagen, 2Bonkolab and 3Institute for Inflammation Research, Rigshospitalet, The University Hospital of Copenhagen, Denmark.

Correspondence to: B. Baslund, Department of Rheumatology TA 4242, The University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E-mail: bbaslund{at}gmail.com


  Abstract

Objective. To examine if polymorphism 80G -> A in the Reduced Folate Carrier (RFC) affects uptake of MTX in B- and CD4+ T-cells.

Methods. Mononuclear cells were isolated from peripheral blood of healthy persons. Real-time PCR was used to detect the RFC80 variants. FITC-labelled MTX was added to cells stimulated with Candida albicans or tetanus toxoid, and the uptake of MTX was measured by flow cytometry. A FITC-conjugated monoclonal antibody against RFC was used to detect the cellular RFC expression.

Results. Antigen-stimulated CD4+ T cells and B cells from individuals with the GG variant (n = 9) exhibited lower uptake of MTX than individuals expressing the AA variant (n = 8), or the GA variant (n = 8). No difference could be demonstrated between the three groups with respect to the expression of RFC by CD4+ T cells and B cells, and CD4+ T cells from individuals homozygous for the G allele exhibited lower uptake of MTX per receptor than CD4+ T cells from individuals homozygous for the A allele.

Conclusion. MTX is taken up more efficiently via the A allele than via the G allele. This difference between the variant forms of RFC suggests that genotyping could be relevant for determining the relevant dosage of MTX in the treatment of neoplastic and autoimmune disease.

KEY WORDS: Methotrexate, Genetic polymorphism, Reduced folate carrier

Submitted 12 November 2007; revised version accepted 30 January 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.